Your request to link to rcsb for CDK2/Cyclin A/Cyclin A1

---

• 1CKP: human cyclin dependent kinase 2 complexed with the inhibitor purvalanol b
• 1DI8: the structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline
• 1DM2: human cyclin-dependent kinase 2 complexed with the inhibitor hymenialdisine
• 1E1V: human cyclin dependent kinase 2 complexed with the inhibitor nu2058
• 1E1X: human cyclin dependent kinase 2 complexed with the inhibitor nu6027
• 1E9H: thr 160 phosphorylated cdk2 - human cyclin a3 complex with the inhibitor indirubin-5-sulphonate bound
• 1F5Q: crystal structure of murine gamma herpesvirus cyclin complexed to human cyclin dependent kinase 2
• 1FIN: cyclin a-cyclin-dependent kinase 2 complex
• 1FQ1: crystal structure of kinase associated phosphatase (kap) in complex with phospho-cdk2
• 1FVT: the structure of cyclin-dependent kinase 2 (cdk2) in complex with an oxindole inhibitor
• 1FVV: the structure of cdk2/cyclin a in complex with an oxindole inhibitor
• 1G5S: crystal structure of human cyclin dependent kinase 2 (cdk2) in complex with the inhibitor h717
• 1GIH: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
• 1GII: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
• 1GIJ: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
• 1GY3: pcdk2/cyclin a in complex with mgadp, nitrate and peptide substrate
• 1GZ8: human cyclin dependent kinase 2 complexed with the inhibitor 2-amino-6-(3'-methyl-2'-oxo)butoxypurine
• 1H00: cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
• 1H01: cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor
• 1H07: cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
• 1H08: cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor
• 1H0V: human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[(r)-pyrrolidino-5'-yl]methoxypurine
• 1H0W: human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[cyclohex-3-enyl]methoxypurine
• 1H1P: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu2058
• 1H1Q: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6094
• 1H1R: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6086
• 1H1S: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6102
• 1H24: cdk2/cyclin a in complex with a 9 residue recruitment peptide from e2f
• 1H25: cdk2/cyclin a in complex with an 11-residue recruitment peptide from retinoblastoma-associated protein
• 1H26: cdk2/cyclin a in complex with an 11-residue recruitment peptide from p53
• 1H27: cdk2/cyclin a in complex with an 11-residue recruitment peptide from p27
• 1H28: cdk2/cyclin a in complex with an 11-residue recruitment peptide from p107
• 1HCK: human cyclin-dependent kinase 2
• 1HCL: human cyclin-dependent kinase 2
• 1JST: phosphorylated cyclin-dependent kinase-2 bound to cyclin a
• 1JSU: p27(kip1)/cyclin a/cdk2 complex
• 1JSV: the structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[(6-amino-4-pyrimidinyl) amino]benzenesulfonamide
• 1JVP: crystal structure of human cdk2 (unphosphorylated) in complex with pkf049-365
• 1KE5: cdk2 complexed with n-methyl-4-{[(2-oxo-1,2-dihydro-3h- indol-3-ylidene)methyl]amino}benzenesulfonamide
• 1KE6: cyclin-dependent kinase 2 (cdk2) complexed with n-methyl-{4- [2-(7-oxo-6,7-dihydro-8h-[1,3]thiazolo[5,4-e]indol-8- ylidene)hydrazino]phenyl}methanesulfonamide
• 1KE7: cyclin-dependent kinase 2 (cdk2) complexed with 3-{[(2,2- dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5- (1,3-oxazol-5-yl)-1,3-dihydro-2h-indol-2-one
• 1KE8: cyclin-dependent kinase 2 (cdk2) complexed with 4-{[(2-oxo- 1,2-dihydro-3h-indol-3-ylidene)methyl]amino}-n-(1,3- thiazol-2-yl)benzenesulfonamide
• 1KE9: cyclin-dependent kinase 2 (cdk2) complexed with 3-{[4- ({[amino(imino)methyl]aminosulfonyl)anilino]methylene}-2- oxo-2,3-dihydro-1h-indole
• 1OGU: structure of human thr160-phospho cdk2/cyclin a complexed with a 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitor
• 1OI9: structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
• 1OIQ: imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation
• 1OIR: imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation
• 1OIT: imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation
• 1OIU: structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
• 1OIY: structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
• 1OKV: cyclin a binding groove inhibitor h-arg-arg-leu-ile-phe-nh2
• 1OKW: cyclin a binding groove inhibitor ac-arg-arg-leu-asn-(m-cl-phe)-nh2
• 1OL1: cyclin a binding groove inhibitor h-cit-cit-leu-ile-(p-f-phe)-nh2
• 1OL2: cyclin a binding groove inhibitor h-arg-arg-leu-asn-(p-f-phe)-nh2
• 1P2A: the structure of cyclin dependent kinase 2 (ckd2) with a trisubstituted naphthostyril inhibitor
• 1P5E: the strucure of phospho-cdk2/cyclin a in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (tbs)
• 1PF8: crystal structure of human cyclin-dependent kinase 2 complexed with a nucleoside inhibitor
• 1PKD: the crystal structure of ucn-01 in complex with phospho- cdk2/cyclin a
• 1PW2: apo structure of human cyclin-dependent kinase 2
• 1PXI: human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2- ylamine
• 1PXJ: human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine
• 1PXK: human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-yl]- n'-hydroxyiminoformamide
• 1PXL: human cyclin dependent kinase 2 complexed with the inhibitor [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- (4-trifluoromethyl-phenyl)-amine
• 1PXM: human cyclin dependent kinase 2 complexed with the inhibitor 3-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2- ylamino]-phenol
• 1PXN: human cyclin dependent kinase 2 complexed with the inhibitor 4-[4-(4-methyl-2-methylamino-thiazol-5-yl)- pyrimidin-2-ylamino]-phenol
• 1PXO: human cyclin dependent kinase 2 complexed with the inhibitor [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2- yl]-(3-nitro-phenyl)-amine
• 1PXP: human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- n',n'-dimethyl-benzene-1,4-diamine
• 1PYE: crystal structure of cdk2 with inhibitor
• 1QMZ: phosphorylated cdk2-cyclyin a-substrate peptide complex
• 1R78: cdk2 complex with a 4-alkynyl oxindole inhibitor
• 1URC: cyclin a binding groove inhibitor ace-arg-lys-leu-phe-gly
• 1URW: cdk2 in complex with an imidazo[1,2-b]pyridazine
• 1V1K: cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
• 1VIN: bovine cyclin a3
• 1VYW: structure of cdk2/cyclin a with pnu-292137
• 1VYZ: structure of cdk2 complexed with pnu-181227
• 1W0X: crystal structure of human cdk2 in complex with the inhibitor olomoucine.
• 1W8C: co-crystal structure of 6-cyclohexylmethoxy-8-isopropyl-9h-purin-2- ylamine and monomeric cdk2
• 1W98: the structural basis of cdk2 activation by cyclin e
• 1WCC: screening for fragment binding by x-ray crystallography
• 1Y8Y: crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor
• 1Y91: crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor
• 1YKR: crystal structure of cdk2 with an aminoimidazo pyridine inhibitor
• 2A0C: human cdk2 in complex with olomoucine ii, a novel 2,6,9- trisubstituted purine cyclin-dependent kinase inhibitor
• 2A4L: human cyclin-dependent kinase 2 in complex with roscovitine
• 2B52: human cyclin dependent kinase 2 (cdk2) complexed with dph- 042562
• 2B53: human cyclin dependent kinase 2 (cdk2) complexed with din- 234325
• 2B54: human cyclin dependent kinase 2 (ckd2)complexed with din- 232305
• 2B55: human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole din-101312
• 2BHE: human cyclin dependent protein kinase 2 in complex with the inhibitor 5-bromo-indirubine
• 2BHH: human cyclin dependent protein kinase 2 in complex with the inhibitor 4-hydroxypiperindinesulfonyl-indirubine
• 2BKZ: structure of cdk2-cyclin a with pha-404611
• 2BPM: structure of cdk2-cyclin a with pha-630529
• 2BTR: structure of cdk2 complexed with pnu-198873
• 2BTS: structure of cdk2 complexed with pnu-230032
• 2C4G: structure of cdk2-cyclin a with pha-533514
• 2C5N: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
• 2C5O: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
• 2C5V: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
• 2C5X: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
• 2C5Y: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
• 2C68: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2C69: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2C6I: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2C6K: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2C6L: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2C6M: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2C6O: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2C6T: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
• 2CCH: the crystal structure of cdk2 cyclin a in complex with a substrate peptide derived from cdc modified with a gamma-linked atp analogue
• 2CCI: crystal structure of phospho-cdk2 cyclin a in complex with a peptide containing both the substrate and recruitment sites of cdc6
• 2CJM: mechanism of cdk inhibition by active site phosphorylation: cdk2 y15p t160p in complex with cyclin a structure
• 2CLX: 4-arylazo-3,5-diamino-1h-pyrazole cdk inhibitors: sar study, crystal structure in complex with cdk2, selectivity, and cellular effects
• 2DS1: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
• 2DUV: structure of cdk2 with a 3-hydroxychromones
• 2EXM: human cdk2 in complex with isopentenyladenine
• 2FVD: cyclin dependent kinase 2 (cdk2) with diaminopyrimidine inhibitor
• 2G9X: structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor nu6271
• 2I40: cdk2/cyclin a complexed with a thiophene carboxamide inhibitor
• 2IW6: structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor
• 2IW8: structure of human thr160-phospho cdk2-cyclin a f82h-l83v- h84d mutant with an o6-cyclohexylmethylguanine inhibitor
• 2IW9: structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor
• 2J9M: crystal structure of cdk2 in complex with macrocyclic aminopyrimidine
• 2JGZ: crystal structure of phospho-cdk2 in complex with cyclin b
• 2R3F: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3G: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3H: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3I: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3J: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3K: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3L: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3M: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3N: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3O: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3P: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3Q: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R3R: crystal structure of cyclin-dependent kinase 2 with inhibitor
• 2R64: crystal structure of a 3-aminoindazole compound with cdk2
• 2UUE: replace: a strategy for iterative design of cyclin binding groove inhibitors
• 2UZB: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
• 2UZD: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
• 2UZE: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
• 2UZL: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
• 2UZN: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
• 2UZO: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
• 2V0D: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
• 2V22: replace: a strategy for iterative design of cyclin binding groove inhibitors
• 2VTA: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTH: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design
• 2VTI: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTJ: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTL: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTM: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTN: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTO: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTP: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.
• 2VTQ: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VTR: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design 13-jun-18 2vtr 1 title
• 2VTS: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.
• 2VTT: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VU3: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
• 2VV9: cdk2 in complex with an imidazole piperazine
• 2W05: structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5b
• 2W06: structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5c
• 2W17: cdk2 in complex with the imidazole pyrimidine amide, compound (s)-8b
• 2W1H: fragment-based discovery of the pyrazol-4-yl urea (at9283), a multi-targeted kinase inhibitor with potent aurora kinase activity
• 2WEV: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
• 2WFY: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
• 2WHB: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
• 2WIH: structure of cdk2-cyclin a with pha-848125
• 2WIP: structure of cdk2-cyclin a complexed with 8-anilino-1- methyl-4,5-dihydro-1h-pyrazolo[4,3-h] quinazoline-3- carboxylic acid
• 2WMA: structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a
• 2WMB: structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a
• 2WPA: optimisation of 6,6-dimethyl pyrrolo 3,4-c pyrazoles: identification of pha-793887, a potent cdk inhibitor suitable for intravenous dosing
• 2WXV: structure of cdk2-cyclin a with a pyrazolo(4,3-h) quinazoline-3-carboxamide inhibitor
• 2X1N: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
• 2XMY: discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents
• 2XNB: discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents
• 3BHT: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 3
• 3BHU: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 5
• 3BHV: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor variolin b
• 3DDP: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor cr8
• 3DDQ: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor roscovitine
• 3DOG: structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor n-&-n1
• 3EID: cdk2/cyclina complexed with a pyrazolopyridazine inhibitor
• 3EJ1: cdk2/cyclina complexed with a pyrazolopyridazine inhibitor
• 3EOC: cdk2/cyclina complexed with a imidazo triazin-2-amine
• 3EZR: cdk-2 with indazole inhibitor 17 bound at its active site
• 3EZV: cdk-2 with indazole inhibitor 9 bound at its active site
• 3F5X: cdk-2-cyclin complex with indazole inhibitor 9 bound at its active site
• 3FZ1: crystal structure of a benzthiophene inhibitor bound to human cyclin- dependent kinase-2 (cdk-2)
• 3IG7: novel cdk-5 inhibitors - crystal structure of inhibitor efp with cdk-2
• 3IGG: novel cdk-5 inhibitors - crystal structure of inhibitor efq with cdk-2
• 3LE6: the structure of cyclin dependent kinase 2 (ckd2) with a pyrazolobenzodiazepine inhibitor
• 3LFN: crystal structure of cdk2 with sar57, an aminoindazole type inhibitor
• 3LFQ: crystal structure of cdk2 with sar60, an aminoindazole type inhibitor
• 3LFS: crystal structure of cdk2 with sar37, an aminoindazole type inhibitor
• 3MY5: cdk2/cyclina in complex with drb
• 3NS9: crystal structure of cdk2 in complex with inhibitor bs-194
• 3PJ8: structure of cdk2 in complex with a pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine.
• 3PXF: cdk2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate
• 3PXQ: cdk2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate
• 3PXR: apo cdk2 crystallized from jeffamine
• 3PXY: cdk2 in complex with inhibitor jws648
• 3PXZ: cdk2 ternary complex with jws648 and ans
• 3PY0: cdk2 in complex with inhibitor su9516
• 3PY1: cdk2 ternary complex with su9516 and ans
• 3QHR: structure of a pcdk2/cyclina transition-state mimic
• 3QHW: structure of a pcdk2/cyclina transition-state mimic
• 3QL8: cdk2 in complex with inhibitor jws-6-260
• 3QQF: cdk2 in complex with inhibitor l1
• 3QQG: cdk2 in complex with inhibitor l2-5
• 3QQH: cdk2 in complex with inhibitor l2-2
• 3QQJ: cdk2 in complex with inhibitor l2
• 3QQK: cdk2 in complex with inhibitor l4
• 3QQL: cdk2 in complex with inhibitor l3
• 3QRT: cdk2 in complex with inhibitor nsk-mc2-55
• 3QRU: cdk2 in complex with inhibitor nsk-mc1-12
• 3QTQ: cdk2 in complex with inhibitor rc-1-137
• 3QTR: cdk2 in complex with inhibitor rc-1-148
• 3QTS: cdk2 in complex with inhibitor rc-2-12
• 3QTU: cdk2 in complex with inhibitor rc-2-132
• 3QTW: cdk2 in complex with inhibitor rc-2-13
• 3QTX: cdk2 in complex with inhibitor rc-2-35
• 3QTZ: cdk2 in complex with inhibitor rc-2-36
• 3QU0: cdk2 in complex with inhibitor rc-2-38
• 3QWJ: cdk2 in complex with inhibitor kvr-1-142
• 3QWK: cdk2 in complex with inhibitor kvr-1-150
• 3QX2: cdk2 in complex with inhibitor kvr-1-190
• 3QX4: cdk2 in complex with inhibitor kvr-1-78
• 3QXO: cdk2 in complex with inhibitor kvr-1-84
• 3QXP: cdk2 in complex with inhibitor rc-3-89
• 3QZF: cdk2 in complex with inhibitor jws-6-52
• 3QZG: cdk2 in complex with inhibitor jws-6-76
• 3QZH: cdk2 in complex with inhibitor kvr-1-124
• 3QZI: cdk2 in complex with inhibitor kvr-1-126
• 3R1Q: cdk2 in complex with inhibitor kvr-1-102
• 3R1S: cdk2 in complex with inhibitor kvr-1-127
• 3R1Y: cdk2 in complex with inhibitor kvr-1-134
• 3R28: cdk2 in complex with inhibitor kvr-1-140
• 3R6X: cdk2 in complex with inhibitor kvr-1-158
• 3R71: cdk2 in complex with inhibitor kvr-1-162
• 3R73: cdk2 in complex with inhibitor kvr-1-164
• 3R7E: cdk2 in complex with inhibitor kvr-1-67
• 3R7I: cdk2 in complex with inhibitor kvr-1-74
• 3R7U: cdk2 in complex with inhibitor kvr-1-75
• 3R7V: cdk2 in complex with inhibitor kvr-1-9
• 3R7Y: cdk2 in complex with inhibitor kvr-2-88
• 3R83: cdk2 in complex with inhibitor kvr-2-92
• 3R8L: cdk2 in complex with inhibitor l3-4
• 3R8M: cdk2 in complex with inhibitor l3-3
• 3R8P: cdk2 in complex with inhibitor nsk-mc1-6
• 3R8U: cdk2 in complex with inhibitor rc-1-132
• 3R8V: cdk2 in complex with inhibitor rc-1-135
• 3R8Z: cdk2 in complex with inhibitor rc-1-136
• 3R9D: cdk2 in complex with inhibitor rc-2-135
• 3R9H: cdk2 in complex with inhibitor rc-2-142
• 3R9N: cdk2 in complex with inhibitor rc-2-21
• 3R9O: cdk2 in complex with inhibitor rc-2-143
• 3RAH: cdk2 in complex with inhibitor rc-2-22
• 3RAI: cdk2 in complex with inhibitor kvr-1-160
• 3RAK: cdk2 in complex with inhibitor rc-2-32
• 3RAL: cdk2 in complex with inhibitor rc-2-34
• 3RJC: cdk2 in complex with inhibitor l4-12
• 3RK5: cdk2 in complex with inhibitor rc-2-72
• 3RK7: cdk2 in complex with inhibitor rc-2-71
• 3RK9: cdk2 in complex with inhibitor rc-2-74
• 3RKB: cdk2 in complex with inhibitor rc-2-73
• 3RM6: cdk2 in complex with inhibitor kvr-2-80
• 3RM7: cdk2 in complex with inhibitor kvr-1-91
• 3RMF: cdk2 in complex with inhibitor rc-2-33
• 3RNI: cdk2 in complex with inhibitor rc-3-86
• 3ROY: cdk2 in complex with inhibitor kvr-1-154
• 3RPO: cdk2 in complex with inhibitor kvr-1-156
• 3RPR: cdk2 in complex with inhibitor rc-2-49
• 3RPV: cdk2 in complex with inhibitor rc-2-88
• 3RPY: cdk2 in complex with inhibitor rc-2-40
• 3RZB: cdk2 in complex with inhibitor rc-2-23
• 3S00: cdk2 in complex with inhibitor l4-14
• 3S0O: cdk2 in complex with inhibitor rc-1-138
• 3S1H: cdk2 in complex with inhibitor rc-2-39
• 3S2P: crystal structure of cdk2 with a 2-aminopyrimidine compound
• 3SQQ: cdk2 in complex with inhibitor rc-3-96
• 3SW4: crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor
• 3SW7: crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor
• 3TI1: cdk2 in complex with sunitinib
• 3TIY: cdk2 in complex with nsc 35676
• 3TIZ: cdk2 in complex with nsc 111848
• 3TNW: structure of cdk2/cyclin a in complex with can508
• 3ULI: human cyclin dependent kinase 2 (cdk2) bound to azabenzimidazole derivative
• 3UNJ: cdk2 in complex with inhibitor yl1-038-31
• 3UNK: cdk2 in complex with inhibitor yl5-083
• 3WBL: crystal structure of cdk2 in complex with pyrazolopyrimidine inhibitor
• 4ACM: cdk2 in complex with 3-amino-6-(4-{[2-(dimethylamino)ethyl]sulfamoyl}- phenyl)-n-pyridin-3-ylpyrazine-2-carboxamide
• 4BCK: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor
• 4BCM: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor
• 4BCN: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor
• 4BCO: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor
• 4BCP: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor
• 4BCQ: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor